F10 and COVID-19: It has previously been demonstrated that prophylactic LMWH dosing is associated with subtherapeutic anti-factor Xa levels in critically ill patients, and therefore an individualized dosing approach based on anti-factor Xa monitoring may be useful in COVID-19 patients [28–31].